The research assesses the safety and efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) versus placebo or antiplatelet therapy following acute myocardial infarction (AMI) in patients with no indication for anticoagulation. A systematic review and network meta-analysis of six randomized controlled trials (RCTs) including 33,039 patients compared rivaroxaban, apixaban, and dabigatran. Rivaroxaban lowered all-cause mortality (risk ratio [RR] 0.82) and likely cardiovascular mortality (RR 0.83), and dabigatran had a likely reduction in all-cause mortality but with low-certainty evidence. Apixaban did not affect mortality outcomes.
People with diabetes or prediabetes face an elevated risk of developing various cardiovascular conditions, including heart disease, stroke, and congestive heart failure. One crucial factor contributing to this increased risk is how well the body utilizes insulin, which can be measured using the estimated glucose disposal rate (eGDR). A lower eGDR score indicates a poorer ability to process insulin and is associated with a higher likelihood of developing heart-related complications.
The meta-analysis revealed that Ivabradine led to an average heart rate reduction of about 11.7 beats per minute compared to placebo treatment. This finding was consistent across different age groups, showing similar benefits in both younger and older patients. The study compiled data from 1,687 participants across 11 randomized clinical trials, with 862 patients receiving Ivabradine and 825 receiving placebo treatment.
The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment
The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment
The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment